Press Releases

BrainStorm to Present at Bio-Asia-International and ARM Investor Day Conferences

NEW YORK and PETACH TIKVAH, Israel, March 8, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, Chief Executive Officer, will be presenting at two upcoming conferences.

BrainStorm Cell Therapeutics

Bio Asia International Conference
Date: Tuesday March 15
Time: 03.15 PM JST - Japan Standard Time (01.15 AM EST)
Location: Grand Hyatt Tokyo, Japan

ARM's (Alliance for Regenerative Medicine) Cell & Gene Investor Day
Date: Tuesday March 22
Time:10.00 AM EST
Location: Metropolitan Club, New York
A live webcast of the conference will be available through the ARM's website at

About the BIO Asia International Conference

The 13th Annual BIO Asia International Conference, co-hosted by the Biotechnology Innovation Organization (BIO), BioCentury and the Japan Bioindustry Association (JBA), brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments. Attendees can gain  insights into the changes, challenges, and opportunities key opinion and policy leaders foresee for the Japanese biotech market.  The conference will take place March 15-16, 2016 at the Grand Hyatt. Tokyo. For more information, refer to

About the ARM Cell & Gene Therapy Investor Day

ARM's Cell & Gene Therapy Investor Day is a full-day conference combining discussions between key opinion leaders, top analysts and senior executives in addition to presentations by the field's most promising companies. The event includes clinical and commercial experts who are on-hand to address specific questions, as well as offer insight into how cell and gene therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. This meeting is open for credentialed investors and members of the media however. RSVP is required. For more information, please go to

About BrainStorm Cell Therapeutics Inc .

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn™ has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the company's website at

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements.  The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at  These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.  The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.


Uri Yablonka, COO
Chief Operating Officer
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188

Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979

Logo -

To view the original version on PR Newswire, visit:

SOURCE BrainStorm Cell Therapeutics Inc.

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds